KeyBank National Association
RYTM icon

KeyBank National Association’s Rhythm Pharmaceuticals RYTM Stock Holding History

KeyBank National Association’s Portfolio RYTM Stock Details RYTM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-3,271
Closed -$350K – 1291
2025
Q4 		$350K Buy
+3,271
New +$347K ﹤0.01% 957

Other funds holding RYTM

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return

KeyBank National Association's RYTM Position: Q1 2026 in Review

KeyBank National Association sold out of Rhythm Pharmaceuticals (RYTM) in Q1 2026, closing a stake of 3,271 shares — an estimated $350K sold.

KeyBank National Association first reported a position in RYTM in Q4 2025 and held it in 1 quarter. The position peaked at $350K in Q4 2025. 285 funds tracked by Wall St. Rank hold RYTM as of Q1 2026.

  • KeyBank National Association reported no remaining Rhythm Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • KeyBank National Association sold 3,271 Rhythm Pharmaceuticals shares in Q1 2026, an estimated $350K.
  • KeyBank National Association first reported a position in Rhythm Pharmaceuticals in Q4 2025 and held it in 1 quarter.
  • KeyBank National Association's Rhythm Pharmaceuticals position peaked at $350K in Q4 2025.
  • 285 funds tracked by Wall St. Rank held Rhythm Pharmaceuticals as of Q1 2026.

Based on KeyBank National Association's 13F filing for Q1 2026, filed 24 Apr 2026.